Essential Medicines and Patents
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the […]
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the […]
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th
Finding and Evaluating Generic Market Entry Opportunities Read Post »
Using data from DrugPatentWatch Fred Ledley and his research group at the Center for Integration of Science and Industry at
Government as the First Investor in Biopharmaceutical Innovation Read Post »
In a recent Bloomberg Law article DrugPatentWatch data is used to show a decrease in patent litigation. This likely means
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th
Finding and Evaluating Market Entry Opportunities for a Better ROI Read Post »
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of
DrugPatentWatch and Bloomberg: Are there too many generic patent challenges? Read Post »
Check out the latest issue of Lab Manager where I discuss my interest in informatics, the complexities of informatics for today’s
Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey